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Introduction
Defects in programmed cell death (apoptosis) mechanisms play
important roles in tumor pathogenesis, allowing neoplastic cells
to survive beyond their normally intended lifespans, subverting
the need for exogenous survival factors, providing protection
from hypoxia and oxidative stress as tumor mass expands, and
allowing time for accumulative genetic alterations that deregu-
late cell proliferation, interfere with differentiation, promote
angiogenesis, and increase cell motility and invasiveness dur-
ing tumor progression (Reed, 1999). In fact, apoptosis defects
are recognized as an important complement to protooncogene
activation, as many deregulated oncoproteins that drive cell
division also trigger apoptosis (e.g., Myc, E1a, Cyclin-D1)
(Green and Evan, 2002). Similarly, defects in DNA repair and
chromosome segregation normally trigger cell suicide as a
defense mechanism for eradicating genetically unstable cells,
and thus apoptosis defects permit survival of genetically unsta-
ble cells, providing opportunities for selection of progressively
aggressive clones (Ionov et al., 2000). Apoptosis defects also
facilitate metastasis by allowing epithelial cells to survive in a
suspended state, without attachment to extracellular matrix
(Frisch and Screaton, 2001). They also promote resistance to
the immune system, inasmuch as many of the weapons cytolyt-
ic T cells (CTLs) and natural killer (NK) cells use for attacking
tumors depend on integrity of the apoptosis machinery
(Tschopp et al., 1999). Finally, cancer-associated defects in
apoptosis play a role in chemoresistance and radioresistance,
increasing the threshold for cell death and thereby requiring
higher doses for tumor killing (Makin and Hickman, 2000).Thus,
defective apoptosis regulation is a fundamental aspect of the
biology of cancer.
When it comes to the successful eradication of cancer
cells by nonsurgical means, ultimately, all roads lead to apop-
tosis. Essentially all cytotoxic anticancer drugs currently in
clinical use, when they work, induce apoptosis of malignant
cells. While microtubule binding drugs, DNA-damaging
agents, and nucleosides are important weapons in the treat-
ment of cancer, a new class of targeted therapeutics may soon
be forthcoming based on strategies that have emerged from a
deeper understanding of the molecular mechanisms that
underlie the phenomenon of apoptosis.
Apoptosis is caused by proteases known as “caspases,” for
cysteine aspartyl-specific proteases (Cryns and Yuan, 1999;
Thornberry and Lazebnik, 1998). Caspases constitute a family
of intracellular cysteine proteases (n = 11 in humans), which
collaborate in proteolytic cascades where caspases activate
themselves and each other. Within these proteolytic cascades,
caspases can be positioned as either upstream “initiators” or
downstream “effectors” of apoptosis. Several pathways for acti-
vating caspases exist (Figure 1). First, of the ?30 members of
the tumor necrosis factor (TNF)-family receptors, eight contain
a so-called death domain (DD) in their cytosolic tail (Locksley et
al., 2001). Several of these DD-containing TNF-family receptors
use caspase activation as a signaling mechanism, including
TNFR1/CD120a, Fas/APO1/CD95, DR3/Apo2/Weasle,
DR4/TrailR1, DR5/TrailR2, and DR6. Ligation of these receptors
at the cell surface results in the recruitment of several intracellu-
lar proteins, including certain procaspases, to the cytosolic
domains of these receptors, forming a “death-inducing signaling
complex” (DISC) that triggers caspase activation—constituting
the so-called “extrinsic” pathway for apoptosis (Wallach et al.,
1999). The specific caspases summoned to the DISC are cas-
pase-8 and, in some cases, caspase-10. These caspases con-
tain so-called death effector domains (DEDs) in their N-terminal
prodomains that bind to a corresponding DED in the adaptor
protein, FADD, thus linking them to the TNF-family death recep-
tor complexes. Second, mitochondria induce apoptosis by
releasing cytochrome-c (cyt-c) into the cytosol, which then
causes assembly of a multiprotein caspase-activating complex,
referred to as the “apoptosome” (Green and Reed, 1998). The
central component of the apoptosome is Apaf1, a caspase-acti-
vating protein that oligomerizes upon binding cyt-c, then binds
procaspase-9 via interaction with its caspase recruitment
domain (CARD). The mitochondrial pathway for apoptosis, also
known as the “intrinsic pathway,” is activated by myriad stimuli,
including growth factor deprivation, oxidants, Ca2+ overload,
oncogene activation, DNA-damaging agents, and microtubule-
attacking drugs. In addition to cyt-c, mitochondria also release
several other proteins, including endonuclease G, AIF (a death-
modulating flavoprotein), and IAP antagonists SMAC (DIABLO)
and OMI (HtrA2) (see below), some of which may promote cas-
pase-independent (nonapoptotic) cell death (Kroemer and
Reed, 2000). A third pathway for apoptosis induction is specific
to CTL and NK cells, which spray apoptosis-inducing protease,
granzyme B (GraB), onto target cells. GraB then piggybacks
into cells via mannose-6-phosphate receptors (IGFR2) and
enters effective cellular compartments via perforin channels
(Motyka et al., 2000). GraB is a serine protease, but similar to
the caspases, it cleaves substrates at Asp residues, including
several caspases and some caspase substrates. Fourth, a cas-
pase activation pathway linked to endoplasmic reticulum
(ER)/Golgi stress has been proposed (Cryns and Yuan, 1999),
though many details are lacking. Finally, a nuclear pathway for
apoptosis regulation may exist which centers on discrete
nuclear organelles, called Pml oncogenic domains (PODs) or
nuclear bodies (NBs). Targeted ablation of the pml gene in mice
results in general resistance to apoptosis through unknown
mechanisms. Several proteins that can promote apoptosis have
been localized to PODs, including Daax, Zip kinase, and Par4,
and defects in assembly of these nuclear structures are docu-
mented in cancers (Salomoni and Pandolfi, 2002). How PODs
are linked to caspase activation pathways is unknown.
Several endogenous antagonists of the caspase-activation
pathways have been discovered and examples of dysregulation
of their expression or function in cancers have been obtained.
These apoptosis suppressors have become targets for drug dis-
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covery, with the idea of abrogating their cytoprotective functions
and restoring apoptosis sensitivity to tumor cells. Alternatively,
one can envision directly activating agonists of apoptosis in
cancer cells. A summary of some of the more promising strate-
gies for modulating the activity of apoptosis genes and proteins
for cancer therapy is provided below, according to the apoptosis
pathways they affect.
Intrinsic pathway
Bcl-2 family proteins (n = 24 in humans) are central regulators
of the intrinsic pathway, which either suppress or promote
changes in mitochondrial membrane permeability required for
release of cyt-c and other apoptogenic proteins (Green and
Reed, 1998; Gross et al., 1999). Overexpression of antiapoptot-
ic Bcl-2 or Bcl-XL probably occurs in more than half of all can-
cers (Amundson et al., 2000), rendering tumor cells resistant to
myriad apoptotic stimuli, including most cytotoxic anticancer
drugs. Attempts to overcome the cytoprotective effects of Bcl-2
and Bcl-XL in cancer include three strategies: (1) shutting off
gene transcription, (2) inducing mRNA degradation with anti-
sense oligonucleotides, and (3) directly attacking the proteins
with small-molecule drugs.
Though not components of the “core” apoptosis machinery,
some members of the steroid/retinoid superfamily of ligand-acti-
vated transcription factors (SRTFs) represent potentially “dru-
gable” modulators of BCL-2 and BCL-XL gene transcription. In
the mammary gland, for example, expression of BCL-2 is estro-
gen-dependent. Consequently, antiestrogens, such as tamox-
ifen, inhibit endogenous BCL-2 expression in breast cancer cell
lines, promoting sensitivity to cytotoxic anticancer drugs such
as doxorubicin. Enforced expression of Bcl-2 protein from plas-
mid vectors, in contrast, abrogates sensitivity to the apoptosis-
promoting effects of antiestrogens in breast cancer lines, while
antisense BCL-2 prevents estrogen-mediated apoptosis sup-
pression, thus establishing a direct functional connection
between ER, Bcl-2, and suppression of apoptosis (Teixeira et
al., 1995). In addition to antiestrogens in
estrogen receptor (ER)-positive breast
cancers, expression of Bcl-2 or Bcl-XL
can be downregulated in specific types
of cancer and leukemia cells by small-
molecule drugs that modulate the activity
of retinoic acid receptors (RAR), retinoid
X receptors (RXR), PPARγ, vitamin D
receptors (VDR), and certain other mem-
bers of the SRTF superfamily. RAR and
RXR ligands are already approved for
treatment of some types of leukemia and
lymphoma, and are in advanced clinical
testing for solid tumors. PPARγ modula-
tors have demonstrated antitumor activi-
ty in xenograft models of breast and
prostate cancer (Kubota et al., 1998),
sometimes displaying synergy with
retinoids, probably due in part to the fact
that PPARγ binds DNA as a heterodimer with RXR.
Interestingly, PPARγ agonist troglitazone can lower serum PSA
in men with advanced prostate cancer, though it is unknown
whether this reflects a proapoptotic mechanism in vivo.
Compounds that inhibit histone deactylases (HDACs), tran-
scriptional repressors that interact with retinoid receptors and
other transcription factors, can also favorably modulate expres-
sion of Bcl-2 or Bcl-XL in some tumor lines (Reed, 2002). These
observations portend opportunities for exploiting endogenous
transcriptional pathways for suppressing expression of antiapo-
ptotic BCL-2-family genes in cancer, with the idea of employing
them as chemo- or radiosensitizers, rather than relying on their
antitumor activity as single agents. However, much remains to
be learned about the genetic characteristics of cancer cells that
dictate responsiveness versus resistance to SRTF-ligands, as
well as the complex pharmacological interplay between this
class of agents and conventional cytotoxic drugs.
Nuclease-resistant (phosphorothioate) antisense oligonu-
cleotides targeting the BCL-2 mRNA have advanced to Phase
III clinical trials for melanoma, myeloma, CLL, and AML, with
Phase II activity underway for a variety of solid tumors (Table 1).
Because BCL-2 antisense enhances sensitivity to cytotoxic
anticancer drugs in vitro and in xenograft models, most clinical
trials combine the antisense agent with conventional
chemotherapy (Chi et al., 2001). Uncontrolled Phase II data
suggest a benefit to adding BCL-2 antisense to conventional
therapy, but definitive proof awaits the Phase III results. Also at
issue is whether phosphorothioate-based oligonucleotides work
entirely through antisense mechanisms.
Strategies for attacking the Bcl-2 and Bcl-XL proteins using
small-molecule drugs have emerged from an understanding of
how our own cells keep these antiapoptotic proteins under con-
trol. In this regard, a large family of endogenous antagonists of
Bcl-2 and Bcl-XL has been revealed (so-called “BH3-only pro-
teins”), possessing a conserved amphipathic α-helical domain
(BH3) that binds a hydrophobic crevice on the surface of Bcl-2
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Figure 1. Apoptosis pathways
Some of the better defined apoptosis pathways
are depicted. FLIP, Bcl-2/Bcl-XL, and IAPs sup-
press specific steps in the extrinsic, intrinsic, and
convergence pathways, respectively.
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and Bcl-XL (Huang and Strasser, 2000). Proof-of-concept
experiments using synthetic BH3 peptides have confirmed the
validity of strategies based on generating small-molecule drugs
that occupy the BH3 binding site on Bcl-2 or Bcl-XL, abrogating
their cytoprotective functions (Letai et al., 2002). Indeed, sever-
al groups have presented preclinical data regarding BH3-mimic-
king compounds (Table 1A). The optimal structure-activity
relation (SAR) profile of these compounds remains to be deter-
mined, with respect to the issue of selective versus broad-spec-
trum activity against the various antiapoptotic members of the
Bcl-2-family (Bcl-2, Bcl-XL, Mcl-1, Bcl-W, Bfl-1, Bcl-B), in terms
of balancing antitumor efficacy against side effects.
Other strategies for countering Bcl-2 and Bcl-XL in cancer
include inducing expression of opposing proapoptotic family
members such as Bax with p53 adenovirus (in Phase III trials)
or with Mda7 (IL-24) adenovirus gene therapy (completed
Phase I trials), as well as Bax adenovirus gene therapy for loco-
regional cancer control (Table 1A). Alternatively, it might be pos-
sible to activate the Bax and Bak proteins using drugs that
mimic agonistic BH3 peptides (Letai et al., 2002).
Extrinsic pathway
The extrinsic pathway is activated in vivo by TNF family ligands
that engage DD-containing receptors, resulting in activation of
DED-containing caspases. The “death ligands” are expressed on
CTLs, NK cells, and other types of immune-relevant cells (activat-
ed monocytes/macrophages and dendritic cells) and are used as
weapons for eradication of transformed cells (Locksley et al.,
2001). Various studies using mice with genetic alterations in
genes encoding death ligands or their receptors, as well as use of
neutralizing antibodies and Fc-fusion proteins, have provided evi-
dence of important roles in tumor suppression by cellular immune
mechanisms. For example, Fas-Ligand (FasL) is important for
CTL-mediated killing of some tumor targets, and TRAIL (Apo2-
Ligand) is critical for NK-mediated tumor suppression.
Interest has emerged in developing therapeutics that kill
cancer cells via the extrinsic pathway, particularly since
chemorefractory cells tend to have defects in their intrinsic path-
way, given the predominant reliance of cytotoxic drugs and x-
irradiation on the mitochondrial pathway for cell death (Green
and Reed, 1998). Attempts to apply TNF as a biological agent
for cancer treatment were stymied by the proinflammatory
effects of this cytokine, due to its simultaneous induction of both
caspase activation pathways and NFκB. In contrast, the TNF
family cytokines FasL and TRAIL trigger activation of the cas-
pase pathway without concomitant induction of NFκB—raising
hopes that they might be successfully exploited for cancer ther-
apy, where TNF failed due to toxicity. While agonistic antibodies
that trigger the receptor Fas (CD95) are unfortunately highly
toxic to liver (Ogasawara et al., 1993), TRAIL and agonistic anti-
bodies that bind TRAIL receptors appear to be well tolerated in
vivo. Indeed, a Phase I trial in humans was recently completed
using an agonistic antibody directed against TRAIL-receptor-1
(TRAIL-R1) (also known as death receptor-4 [DR4]) (Table 1B).
In mouse xenograft models using selected tumor human cells
lines, TRAIL and agonistic antibodies directed against TRAIL
receptors have been demonstrated to possess potent antitumor
activity (Ashkenazi et al., 1999), raising hopes of using these
biological agents as a novel approach to cancer treatment and
thereby mimicking some of the effector mechanisms normally
employed by the immune system in its defense against trans-
formed cells, and potentially bypassing the roadblocks to apop-
F O C U S
Table 1. Summary of drug discovery activity targeting core components of the apoptosis machinery
Agent/strategy Group/company Current status
A. Bcl-2/Bcl-XL antagonists
Bcl-2 antisense (G3139) GENTA/Aventis Phase II and III
Bcl-2/Bcl-XL small-molecule antagonists IDUN/Abbott Preclinical
Bcl-2 small-molecule antagonist (GX-01) Gemin-X Preclinical
Bcl-2 small-molecule antagonist Structural Bioinformatics Preclinical
Bcl-2 small-molecule antagonists Thomas Jefferson University; Preclinical
Harvard University
Washington University
Bcl-2 inhibitory natural product (Tetrocarcin-A) Kyowa-Hakko Kogyo Preclinical
Bax adenovirus MD Anderson Cancer Center; Phase I
University of South Carolina
BH3 mimetics (peptides) Biomeasure Preclinical
B. TRAIL-R agonists
Anti-DR4 monoclonal agonist Human Genome Sciences Phase I
(Cambridge Antibody)
Anti-DR5 monoclonal agonist Sankyo Preclinical
TRAIL extracellular domain Genentech-Immunex (Amgen) Preclinical
C. IAP-antagonists
SMAC-mimicking small molecules IDUN/Abbott Preclinical
Survivin antisense ISIS/Lilly Preclinical
XIAP antisense Agera Preclinical
Some of the current activity toward discovery and development of apoptosis-based therapies for cancer is summarized for (A) Bcl-2/Bcl-XL antagonists, (B)
TRAIL-Receptor agonists, and (C) IAP-antagonists. Data are based on a combination of published reports, patent applications, meeting reports, press
releases, and internet-derived information.
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tosis within the intrinsic (mitochondrial) pathway.
Unfortunately, many tumor cell lines display intrinsic resis-
tance to TRAIL, despite expressing the necessary cell-surface
receptors. This observation implies that during evolution of
tumors in vivo, selection occurs for malignant clones capable of
withstanding immune attack, and thus, successful biological
therapy depends on restoring competency of the extrinsic path-
way. A possible mechanism for accomplishing this goal has
recently been revealed by studies of synthetic triterpenoids,
such as CDDO and CDDOm, that trigger a poorly defined path-
way for ubiquitination and degradation of FLIP (Kim et al., 2002;
Pedersen et al., 2002), an apoptosis-modulating protein that
binds procaspase-8 and -10 (Tschopp et al., 1999). At least in
vitro, these compounds sensitize solid tumor cell lines to TRAIL,
and induce apoptosis as single agents in leukemia cells,
through a caspase-8-dependent mechanism that remains oper-
ative even in chemorefractory cells (Ito et al., 2000; Kim et al.,
2002; Pedersen et al., 2002). It remains to be determined
whether these promising observations will hold up in vivo.
Other routes to engaging the extrinsic pathway have recent-
ly been revealed that may apply at least to leukemia. For exam-
ple, the protein kinase C (PKC) modulator byrostatin induces
myeloid leukemia cell lines to produce TNF, resulting in
autocrine engagement of TNF-receptors and apoptosis induc-
tion through a mechanism that is suppressible by TNFR-Fc
fusion protein and caspase-8 dominant-negative (Cartee et al.,
2002). Similarly, all-trans-retinoic acid (ATRA) induces TRAIL
production and triggers autocrine induction of apoptosis in
acute promyelomonocytic leukemia (APML) cells that harbor
the RARα-PML fusion protein resulting from t(15;17) chromoso-
mal translocations (Altucci et al., 2001). It remains to be deter-
mined whether similar autocrine loops can be activated by
these agents in solid tumors.
Convergence pathway
Ultimately, the intrinsic and extrinsic pathways for caspase acti-
vation converge on downstream effector caspases (Figure 1).
Mechanisms for suppressing apoptosis at this distal step in cell
death pathways have been revealed, and their relevance to can-
cer is becoming progressively obvious. In this regard, the
inhibitor of apoptosis proteins (IAPs) represent a family of evo-
lutionarily conserved apoptosis suppressors (n = 8 in humans),
many of which function as endogenous inhibitors of caspases
(Deveraux and Reed, 1999). All members of this family, by defi-
nition, contain at least one copy of a so-called BIR (baculovirus
iap repeat) domain, a zinc binding fold, which is important for
their antiapoptotic activity, present in 1–3 copies. Among the
caspases directly inhibited by human IAP family members XIAP,
cIAP1, and cIAP2 are effector caspases-3 and -7, as well as ini-
tiator caspase-9 (intrinsic pathway). For XIAP, the second BIR
domain and the linker region between BIR1 and BIR2 are
required for binding and suppressing caspases-3 and -7, while
the third BIR domain binds caspase-9. Thus, different domains
in the multi-BIR containing IAPs are responsible for suppression
of different caspases. IAP family member Livin (ML-IAP) con-
tains a single BIR and inhibits caspase-9 but not caspase-3 and
-7. Survivin also contains a single BIR and reportedly associ-
ates with caspase-9, though its mechanism of caspase sup-
pression is poorly defined.
Pathological overexpression of IAPs occurs in many can-
cers, though more detailed information is needed about which
of the 8 members of this gene family is deregulated in specific
types of cancer. Antisense-mediated reductions in IAP-family
members XIAP, cIAP1, Survivin, or Apollon can induce apopto-
sis of tumor cell lines in culture, or sensitize cells to cytotoxic
anticancer drugs, thus providing proof-of-concept evidence that
the pathological elevations of IAPs found in cancers are impor-
tant for maintaining tumor cell survival and resistance to
chemotherapy (Table 1C).
Endogenous antagonists of IAPs help to keep these apop-
tosis suppressors in check, promoting apoptosis. Two of these
naturally occurring IAP-antagonists, SMAC (Diablo) and HtrA2
(Omi), are sequestered inside mitochondria, becoming
released into the cytosol during apoptosis (Reed, 2002). SMAC
and HtrA2 have N-terminal leader sequences that are removed
F O C U S
Figure 2. Signal transduction and apoptosis regulation
Some protein kinases and transcription factors are well known for their abil-
ity to modulate activity or expression of apoptosis-relevant proteins. The fig-
ure shows examples for (A) NFκB, (B) Akt, and (C) p53.
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by proteolysis upon import into mitochondria, exposing a novel
tetrapeptide motif that binds the BIR domains of IAPs. These
IAP antagonists compete with caspases for binding to IAPs,
thus freeing caspases from the grip of the IAPs and promoting
apoptosis. Synthetic peptides that mimic SMAC and HtrA2 trig-
ger apoptosis or sensitize tumor cell lines to apoptosis induced
by cytotoxic anticancer drugs or TRAIL in vitro and even in
some tumor xenograft models (Fulda et al., 2002). Structural
information derived from high-field NMR and X-ray crystallogra-
phy indicates that a tetrapeptide motif is sufficient to bind the
BIRs of IAPs, suggesting a path to drug discovery where small-
molecule chemical compounds that occupy the same tetrapep-
tide binding motif on BIRs can be envisioned as new
apoptosis-sensitizing agents for cancer (Wu et al., 2000).
However, many issues remain unresolved, including the ques-
tions of which IAP-family members, and which BIR domains
within those IAPs, should be targeted by drugs.
Multipathway regulators
Though not core components of the cell death machinery, cer-
tain signaling proteins have emerged as potential drug targets
for modulating apoptosis pathways, based on their ability to influ-
ence the expression or function of other proteins. Some of these
apoptosis-modulating proteins may impact several apoptosis
pathways simultaneously, possibly at multiple points. For exam-
ple, NFκB family transcription factors can induce expression of
antiapoptotic proteins that oppose the intrinsic (Bcl-XL, Bfl-1),
extrinsic (FLIP), and convergence (cIAP2) pathways (Figure 2A),
as well as suppressing expression of the death inducer Bax
(intrinsic pathway) in some types of tumor cells (Karin and Lin,
2002). Further, hyperactivity of NFκB is now well documented in
certain cancers (Karin et al., 2002). Consequently, agents that
inhibit NFκB activation are desired, and are currently being pur-
sued, based on strategies that seek to maintain levels of
endogenous NFκB-inhibiting IκB-family proteins, by either sup-
pressing the IκB kinases (IKKs) responsible for phosphorylation
of IκBα (which induces its polyubiquitination) or blocking the pro-
teolytic activity of the 26s proteasome responsible for degrading
IkB following ubiquitination (Figure 2A).
Similarly, Akt (PKB) directly phosphorylates multiple protein
targets of relevance to apoptosis (Figure 2B), suppressing cell
death clearly within the intrinsic pathway (e.g., BAD inactiva-
tion, human caspase-9 suppression) and possibly also the
extrinsic pathway (e.g., FasL expression) in some types of cells.
Pathological elevations in Akt activity are a common occurrence
in tumors, due to loss of tumor suppressor PTEN, hyperactivity
of PI3K-activating growth factors receptors and oncoproteins,
and other mechanisms (Testa and Bellacosa, 2001). Small-mol-
ecule drugs that occupy the ATP binding pocket of the catalytic
domain of Akt thus represent a highly attractive approach to
restoration of apoptosis sensitivity in cancers, and would also
be expected to have additional benefits on cell proliferation and
cell growth. While the PH domain of Akt that binds second-mes-
senger phospholipids involved in Akt activation could theoreti-
cally be targeted by drugs, the hydrophilic interactions
associated with coordinating polyphosphorylated lipids do not
lend themselves well to membrane permeable compounds.
The transcription factor p53 reportedly regulates the
expression of multiple apoptosis-regulating genes that affect
either the intrinsic or extrinsic pathways (Figure 2C), though the
specific targets of p53 that are most relevant probably differ
widely among tissues and tumor types (Vogelstein et al., 2000).
Clinical trials are underway using gene therapy-based
approaches for restoring p53 activity in deficient cancers, which
might permit better loco-regional control of cancer in combina-
tion with radiotherapy.
In addition to NFκB, Akt, and p53, multiple cancer-relevant
proteins that operate upstream of these factors could to some
extent be viewed as apoptosis modulators, though acting rather
indirectly on the core cell death machinery. Therapies targeting
these upstream inducers include many biological agents, such
as: (1) monoclonal antibodies recognizing cell surface receptors
(e.g., anti-HER2 [Herceptin], anti-EGFR [Erbitux]), (2) small
molecule drugs that target the kinase domains of these recep-
tors and other oncogenic protein tyrosine kinases (e.g.,
EGFR/Iressa, BCR-ABL/Gleevec), which presumably suppress
PI3K/Akt activation, and (3) anti-CD40L antibodies and CD40L
adenovirus gene therapy, which modulate NFκB activity.
Monoclonal antibodies targeting the tetra-span membrane pro-
tein CD20 (Rituximab) also can downregulate expression of
Bcl-2-family member Mcl-1 (intrinsic pathway) and XIAP (con-
vergence pathway) in certain leukemias, providing yet another
example of unexpected links to apoptosis pathways through
receptor-mediated signaling, in a context relevant to cancer
treatment (Byrd et al., 2002). Thus, abundant opportunities may
exist for exploiting receptor targeting agents for indirectly restor-
ing apoptosis sensitivity in cancer, representing an area worthy
of further in-depth exploration.
Conclusions
From an improved understanding of apoptosis mechanisms,
multiple novel strategies have emerged for restoring apoptosis
sensitivity in cancer, and clinical testing of several of these
approaches is underway. Much remains to be learned about
how best to exploit these new potential therapies, matching
genetic lesion in cancers to the optimal agent. It remains to be
determined to what extent toxicity to normal tissues will limit
application of apoptosis-based therapies for cancer treatment.
Cancer cells, however, may be relatively more dependent on
apoptosis suppression than normal cells, due to aberrations in
protooncogene activity and cell cycle checkpoint control, wan-
dering of cancer cells from their normal sites of trophic support,
and hypoxic conditions caused by inadequate vascular supply.
Exploiting this differential dependence on apoptosis-suppress-
ing mechanisms offers hope that improved clinical outcomes
may not be far from realization.
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